 SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 PRNewswire -- Oncolytics Biotech Inc. NASDAQ: ONCY TSX: ONC today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. 